Menu Search
Equities

Nasmed Ozel Saglik Hizmetleri Ticaret AS

EGEPO.E:IST

Nasmed Ozel Saglik Hizmetleri Ticaret AS

Actions
Health CareHealth Care Providers
  • Price (TRY)20.48
  • Today's Change0.10 / 0.49%
  • Shares traded640.40k
  • 1 Year change-3.58%
  • Beta--
Data delayed at least 15 minutes, as of Jun 21 2024 16:08 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nasmed Ozel Saglik Hizmetleri Ticaret AS is a Turkey-based company, which is doing business as Egepol Hospitals Group and provides health care services. The Company offers cardiovascular surgery, intensive care, home healthcare, gastroenterology, general surgery, gynecological, oncology, endocrine surgery and other medical services. Additionally entity provides services related to psychiatry, palliative care, procotology, pulmonology, radiology, rheumatology, ophthalmology, orthopedics, traumatology, neurology and mammaplasty areas of treatment. Egepol Hospitals Group serves patients in Turkey.

  • Revenue in TRY (TTM)732.18m
  • Net income in TRY64.99m
  • Incorporated2003
  • Employees676.00
  • Location
    Nasmed Ozel Saglik Hizmetleri Ticaret ASGunesli Mahallesi 529 Sokak 2/A KonakIzmir TurkeyTUR
  • Phone+90 2 322629988
  • Fax+90 2 322629940
  • Websitehttps://www.egepolhastanesi.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.